NEO, US64049M2098

NeoGenomics stock fell 3.48 percent to USD 16.65 on October 16

Published on 10/17/2026 at 21:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Needham set a USD 22.00 target on October 6, 2026. NeoGenomics stock cost USD 16.65 on October 16, 2026, down 3.48 percent on Nasdaq.

Price and valuation

NeoGenomics stock fell 3.48 percent on Nasdaq on October 16, 2026.
Needham set a USD 22.00 target on October 6, 2026, 32.13 percent above the last Nasdaq price.
NeoGenomics stock was last at USD 16.65 at 4:00 p.m. ET on October 16, 2026, down 3.48 percent versus the Nasdaq prior close.
NeoGenomics will report third-quarter 2026 results on October 28, 2026.

NEO, US64049M2098, Illustration mit AI erstellt.

NeoGenomics stock was last at USD 16.65 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 3.48 percent from the prior close of USD 17.25. The move leaves the stock below a recent analyst target and ahead of its next scheduled results.

Needham target remains above price

Needham raised its price target for NeoGenomics from USD 19.00 to USD 22.00 on October 6, 2026, while maintaining a Buy rating, according to Investing.com. The target stands 32.13 percent above the Nasdaq price of USD 16.65, calculated in the same currency.

Price position after October 16

NeoGenomics traded between USD 16.44 and USD 17.45 on October 16, 2026. Its 52-week range ran from USD 7.07 to USD 20.15, leaving the last price 17.37 percent below the high and 135.50 percent above the low. Volume reached 2,308,887 shares against an average of 2,197,032, or 5.09 percent higher.

Results date is October 28

Market capitalization stood at USD 2.2 billion on October 16, 2026. NeoGenomics is scheduled to report third-quarter 2026 results after the U.S. market close on October 28, 2026, with a conference call at 4:30 p.m. ET, according to Nasdaq. The date gives investors a defined point for assessing the company after its latest share-price decline.

Comparison with peers

NEO (Nasdaq, USD): minus 3.48 percent, market capitalization USD 2.2 billion.

Thermo Fisher Scientific (NYSE, USD): minus 0.93 percent, P/E 37.12, market capitalization USD 255.1 billion.

Quest Diagnostics (NYSE, USD): minus 1.74 percent, P/E 24.95, market capitalization USD 25.9 billion.

Last Nasdaq price

NeoGenomics was last at USD 16.65 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 3.48 percent versus the Nasdaq prior close of USD 17.25. The next scheduled reporting date is October 28, 2026.